Prolexys Pharmaceuticals is a biopharmaceutical firm that specializes in the discovery of small-molecule drugs that act against novel therapeutic targets. The company s therapeutic focus is on cancer and cardiovascular indications. Its ability to identify and validate therapeutic targets is driven by technological expertise in the field of proteomics. Prolexys Pharmaceuticals features the HyNet yeast-hybrid system and HySpec mass spectrometry-based protein technology. The HyNet system has been used to create an extensive database of human protein interactions. It expands the biochemical network for the discovery of new protein relationships. Prolexys Pharmaceuticals was formed in 2001 and is based in Salt Lake City.